US6770745B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Common gamma chain blocking agents
Assignee: Biogen MA Inc
•
Filing: 2001-04-02
•
Granted: 2004-08-03
•
Expires: 2021-04-02
Abstract
Abstract The invention relates to antibodies which specifically bind to the gc chain of cytokine receptors, as well as to cell lines which produce such antibodies, pharmaceutical compositions, and methods of treating immunological diseases by treating patients with such antibodies.
Inventors
- 👤 Linda C. Burkly
- 👤 Christopher D. Benjamin
- 👤 Catherine Hession
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 02:42
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/715; C07K14/7155; C07K16/00; C07K16/18; C07K16/28; C07K16/2866; A; A61; A61K; A61K38/00; A61K39/00; C07K2319/00
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
191 words
A pharmaceutical composition which comprises an effective amount of a gamma common chain blocking agent wherein the agent is a monoclonal antibody selected from the group consisting of: (a) a monoclonal antibody that cross competes with monoclonal antibody CP.B8 produced by hybridoma cell line ATCC No. HB-12107 for binding to gc chain, and also cross competes with Fab, F(ab′) 2 , and Fv fragments and conjugates of said CP.B8; (b) a monoclonal antibody that cross competes with monoclonal antibody CQ.C11 produced by hybridoma cell line ATCC No. HB-12105 for binding to gc chain, and also cross competes with Fab, F(ab′) 2 , and Fv fragments and conjugates of said CQ.C11; (c) a monoclonal antibody that cross competes with monoclonal antibody AF.F4 produced by hybridoma cell line ATCC No. HB-12104 for binding to gc chain, and cross competes Fab, F(ab′) 2 , and Fv fragments and conjugates of said AF.F4; and (d) a monoclonal antibody that cross competes with the monoclonal antibody AE.C9 produced by hybridoma cell line ATCC No. HB-12106 for binding to gc chain, and cross competes with Fab. F(ab′) 2 , and Fv fragments and conjugates of said AE.C9.
Claim 2
Dependent Claim
191 words
A pharmaceutical composition which comprises an effective amount of a gamma common chain blocking agent wherein the agent is a monoclonal antibody selected from the group consisting of: (a) a monoclonal antibody that cross competes with monoclonal antibody CP.B8 produced by hybridoma cell line ATCC No. HB-12107 for binding to gc chain, and also cross competes with Fab, F(ab′) 2 , and Fv fragments and conjugates of said CP.B8; (b) a monoclonal antibody that cross competes with monoclonal antibody CQ.C11 produced by hybridoma cell line ATCC No. HB-12105 for binding to gc chain, and also cross competes with Fab, F(ab′) 2 , and Fv fragments and conjugates of said CQ.C11; (c) a monoclonal antibody that cross competes with monoclonal antibody AF.F4 produced by hybridoma cell line ATCC No. HB-12104 for binding to gc chain, and cross competes Fab, F(ab′) 2 , and Fv fragments and conjugates of said AF.F4; and (d) a monoclonal antibody that cross competes with the monoclonal antibody AE.C9 produced by hybridoma cell line ATCC No. HB-12106 for binding to gc chain, and cross competes with Fab. F(ab′) 2 , and Fv fragments and conjugates of said AE.C9.
References Cited (Backward Citations)
EP0125023A1
Cited
WO1992018534A1
Cited
WO1993016723A1
Cited
EP0578932A2
Cited
US5510259A
Cited
EP0621338A2
Cited
US5582826A
Cited
WO1996012733A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2007-08-03 | 2008-02-02 | 2008-08-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2011-08-03 | 2012-02-02 | 2012-08-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2015-08-03 | 2016-02-02 | 2016-08-03 | $7700.00 | Window Closed / Lapsed |